News

Raptor Pharmaceutical recently announced new clinical data from a Phase 3 trial evaluating the efficacy of Quinsair (levofloxacin) versus tobramycin in cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas aeruginosa. Study results were presented at the 39th European Cystic Fibrosis Conference in Basel, Switzerland. “Patients with cystic fibrosis have few…

TGV-inhalonix reported clinical findings at the European Cystic Fibrosis Conference recently Basel, Switzerland, that show the potential of a new drug to treat mixed bacterial and fungal lung infections contracted by patients with cystic fibrosis (CF). The data presented by George Tetz, scientific and development advisor of TGV-inhalonix, indicated that Mul-1867…

Researchers at the University of Iowa have uncovered a link between the dysfunction of cystic fibrosis protein CFTR and airway smooth muscle (ASM) abnormalities — two common pathologies of the chronic lung disorder cystic fibrosis (CF). The study, “Acute administration of ivacaftor to people with cystic fibrosis and a…

Swiss Pharmaceutical company Polyphor has successfully completed its Phase I clinical trial in healthy volunteers for the investigational inhaled POL6014. POL6014 is a selective and reversible inhibitor of human neutrophil elastase (hNE), a key target for the treatment of respiratory diseases like cystic fibrosis (CF). Cystic fibrosis is a genetic…

The Boomer Esiason Foundation (BEF), a partnership of medical and business leaders dedicated to increasing awareness, education, and quality of life for people living with cystic fibrosis (CF), recently announced the premiere of the documentary “Up for Air” on June 20 in a private screening in New York City. The documentary follows…

Healthcare workers with cystic fibrosis (CF) are more likely to contract methicillin-resistant staphylococcus aureus (MRSA) infections than CF patients not in healthcare scenarios, according to the study “Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study,” published in BMC Pulmonary Medicine. MRSA infection is caused…

A new study from the University of Iowa might show that an old drug can be used in a new way: to treat cystic fibrosis airway disease. The research report, “Repurposing tromethamine as inhaled therapy to treat CF airway disease,“ appeared in the scientific journal…

Ireland’s National Centre for Pharmacoeconomics (NCPE) stirred the pot this week with its decision that the cost of the new cystic fibrosis (CF) drug Orkambi is not justified by its acknowledged benefits, and should not be paid for by the Irish Health Service Executive. The regulatory agency, whose mission is…

The bacterium Burkholderia multivorans grows, evolves and adapts to life inside the lungs of patients with cystic fibrosis, according to the results of a study recently published in the journal mSystems. The study, “Long-Term Evolution of Burkholderia multivorans during a Chronic Cystic Fibrosis Infection Reveals Shifting Forces of Selection,”…

Researchers partially restored the function of the CFTR protein in lung cells isolated from cystic fibrosis (CF) patients by blocking a particular protein involved in its translation. The findings were published in the journal PLOS Biology, in the study “Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional…